Back to Journals » Therapeutics and Clinical Risk Management » Volume 14

Review

Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma

      
Total article views   HTML views PDF downloads Totals
20,307 Dovepress* 11,770+ 2,077 13,847
PubMed Central* 8,537 1,504 10,041
Totals 20,307 3,581 23,888
*Since 31 May 2018
Total mentioned Facebook Delicious Reddit Twitter Others
2 0 0 0 1 1

View citations on PubMed Central and Google Scholar